{
    "clinical_study": {
        "@rank": "129603", 
        "arm_group": [
            {
                "arm_group_label": "Treatment", 
                "arm_group_type": "Experimental", 
                "description": "Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and\n      octreotide therapy is superior to the standard of care alone in the treatment of Type I\n      hepatorenal syndrome in the first 14 days of hospitalization."
        }, 
        "brief_title": "Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatorenal Syndrome", 
        "condition_browse": {
            "mesh_term": "Hepatorenal Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Each hospitalized subject will undergo pre-dosing screening with review of his or her\n      history and physical exam from the day of enrollment and safety assessment to ensure no\n      contraindication to use of PTX.  Type I HRS will be defined according to the criteria put\n      forth by the American Association for the Study of Liver Disease as (1) cirrhosis with\n      ascites; (2) serum creatinine greater than 1.5 mg/dL; (3) no improvement of serum creatinine\n      (decrease to a level of 1.5 mg/dL or less) after at least two days with diuretic withdrawal\n      and volume expansion with albumin;  (4) absence of shock; (5) no current or recent treatment\n      with nephrotoxic drugs; and (6) absence of parenchymal kidney disease as indicated by\n      proteinuria >500 mg/day, microhematuria (>50 red blood cells per high power field), and/or\n      abnormal renal ultrasonography.  Baseline testing will be obtained from hospitalization\n      records, including but not limited to chemistry panel, liver function testing, urinalysis,\n      urine electrolytes, coagulation studies, blood cultures, chest x-ray, diagnostic\n      paracentesis, abdominal ultrasound with Doppler.\n\n      Subjects will take either placebo three times a day or pentoxyfylline 400mg three times a\n      day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in\n      addition to standard AMO therapy.  Treatment will be continued for 14 days unless a study\n      endpoint has been reached at which time either PTX or placebo will be stopped"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hospitalized patients with acute or chronic liver disease\n\n          -  Type I HRS\n\n          -  Aged greater than or equal to 18\n\n          -  Non-pregnant\n\n        Exclusion Criteria:\n\n          -  Allergy or hypersensitivity to PTX or intolerance to methylxanthines (e.g.  caffeine,\n             theophylline)\n\n          -  Concurrent use of nephrotoxic drugs\n\n          -  Age less than 18\n\n          -  Pregnancy\n\n          -  Uncontrolled bacterial infection\n\n          -  Renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease,\n             interstitial nephritis and urinary obstruction)\n\n          -  Shock\n\n          -  TNF alpha antagonist use\n\n          -  Subject is institutionalized or a prisoner\n\n          -  Recent cerebral or retinal hemorrhage (contraindication to PTX)\n\n          -  Severe or poorly controlled cardiovascular disease as determined by the principal\n             investigator to hinder the ability to adhere to study protocols"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123576", 
            "org_study_id": "17365"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Pentoxyfylline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment", 
                    "Placebo"
                ], 
                "description": "Albumin, midodrine and octreotide therapy (standard of care for HRS)", 
                "intervention_name": "AMO Therapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pentoxifylline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatorenal syndrome", 
            "Renal failure", 
            "Pentoxyfylline", 
            "Liver transplantation", 
            "Cirrhosis"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "contact": {
                "email": "jgs9f@virginia.edu", 
                "last_name": "Jonathan G Stine, MD", 
                "phone": "434-924-2959"
            }, 
            "contact_backup": {
                "email": "northup@virginia.edu", 
                "last_name": "Patrick G Northup, MD MHS", 
                "phone": "4349252959"
            }, 
            "facility": {
                "address": {
                    "city": "Charlottesville", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "22908"
                }, 
                "name": "University of Virginia Health System"
            }, 
            "investigator": [
                {
                    "last_name": "Jonathan G Stine, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Patrick G Northup, MD MHS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Stephen H Caldwell, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nic Intagliata, MD MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Curtis K Argo, MD MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Neeral Shah, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study", 
        "overall_contact": {
            "email": "jgs9f@virginia.edu", 
            "last_name": "Jonathan G Stine, MD", 
            "phone": "4349242959"
        }, 
        "overall_contact_backup": {
            "email": "northup@virginia.edu", 
            "last_name": "Patrick G Northup, MD", 
            "phone": "4349242959"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Virginia", 
                "last_name": "Patrick G Northup, MD MHS", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Virginia", 
                "last_name": "Jonathan G Stine, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death", 
            "measure": "Incidence of treatment success", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "reference": [
            {
                "PMID": "11113103", 
                "citation": "Morgan TR, McClain CJ. Pentoxifylline and alcoholic hepatitis. Gastroenterology. 2000 Dec;119(6):1787-91. Review."
            }, 
            {
                "PMID": "21396970", 
                "citation": "Angeli P. \u03b2-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. J Hepatol. 2011 Oct;55(4):743-4. doi: 10.1016/j.jhep.2011.02.026. Epub 2011 Mar 10."
            }, 
            {
                "PMID": "20054052", 
                "citation": "Lott JP. Renal failure in cirrhosis. N Engl J Med. 2010 Jan 7;362(1):79; author reply 80-1. doi: 10.1056/NEJMc0910190."
            }, 
            {
                "PMID": "2454887", 
                "citation": "Spring FA, Dalchau R, Daniels GL, Mallinson G, Judson PA, Parsons SF, Fabre JW, Anstee DJ. The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology. 1988 May;64(1):37-43."
            }, 
            {
                "PMID": "18628385", 
                "citation": "Fallon E, Ehrenwald E, Nazarian GK, Smith CI. TIPS with a polytetrafluoroethylene-lined stent graft and associated haemolytic anaemia. Gut. 2008 Aug;57(8):1180-1."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123576"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Virginia", 
            "investigator_full_name": "Patrick Northup, MD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in serum creatinine from baseline", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Defined as creatinine level above baseline value after day 7, dialysis or death", 
                "measure": "Incidence of treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Day14"
            }, 
            {
                "description": "We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence", 
                "measure": "Combined increase of treatment success and \"partial response", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Transplant free survival", 
                "safety_issue": "No", 
                "time_frame": "day 30 and 180"
            }, 
            {
                "description": ".This will be the combination of transplant free survival and those patients who received liver transplant", 
                "measure": "Composite survival index", 
                "safety_issue": "No", 
                "time_frame": "day 30 and 180"
            }
        ], 
        "source": "University of Virginia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Patrick Northup, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}